NCT01804101View on ClinicalTrials.gov

Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia

NACompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

May 7, 2013

Primary Completion Date

January 10, 2017

Study Completion Date

January 10, 2017

Conditions
Acute Biphenotypic LeukemiaAcute Myeloid LeukemiaMyelodysplastic SyndromeUntreated Adult Acute Myeloid Leukemia
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Liposomal Cytarabine-Daunorubicin CPX-351

Given IV

Trial Locations (2)

94304

Stanford Cancer Institute, Palo Alto

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT01804101 - Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter